LPTX:NAS (USA)

Leap Therapeutics Inc

$ 1.72 0.03 (1.78%)
Volume: 231,662 Avg Vol (1m): 1,187,769
Market Cap $: 38.29 Mil Enterprise Value $: 15.04 Mil
P/E (TTM): 0.00 P/B: 2.96
Earnings Power Value 1.44
Net Current Asset Value 0.47
Tangible Book 0.58
Projected FCF 0
Median P/S Value 0
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
YTD (-%)

Financial Strength : 4/10

Current vs industry vs history
Cash-to-Debt No Debt
Altman Z-Score -9.95
DISTRESS
GREY
SAFE
WACC vs ROIC %
ROIC 0%
WACC 14.94%

Profitability & Growth : 3/10

Current vs industry vs history
ROE % -209.65
ROA % -77.98
ROC (Joel Greenblatt) % -20885.17
3-Year Total EBITDA Growth Rate -13.40
3-Year EPS w/o NRI Growth Rate -15.50

» LPTX's 30-Y Financials

Financials (Next Earnings Date: 2019-05-17)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:LPTX

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325414    SIC : 2836
Compare NAS:KRYS NAS:EIGR OSTO:MVIR B OTCPK:NWBO OTCPK:CYDY TPE:1733 NAS:KALV XPAR:GNRO FRA:PB9 OSL:TRVX NAS:OPHT ASX:MDC ROCO:4193 TSE:4572 TSX:APS LSE:DDDD XMCE:ORY NAS:BLRX NAS:MACK NAS:CDTX
Traded in other countries
Address 47 Thorndike Street, Suite B1-1, Cambridge, MA, USA, 02141
Leap Therapeutics Inc is a biopharmaceutical company. The company is acquiring and developing novel therapeutics at the leading edge of cancer biology. Its programs are monoclonal antibodies that target key cellular pathways that enable cancer to grow and spread and specific mechanisms that activate the body's immune system to identify and attack cancer. Leap has two clinical stage programs: DKN-01 and TRX518. DKN-01 is a monoclonal antibody targeting Dickkopf-related protein 1, or DKK1, a protein that regulates important cell signaling pathways, known as the Wnt pathways. TRX518 is a monoclonal antibody targeting the glucocorticoid-induced tumor necrosis factor-related receptor, or GITR, a receptor found on the surface of a wide range of immune cells.

Ratios

Current vs industry vs history
PB Ratio 2.96
EV-to-EBIT -0.65
EV-to-EBITDA -0.66
Current Ratio 4.03
Quick Ratio 4.03

Dividend & Buy Back

Current vs industry vs history
3-Year Share Buyback Rate 8.80

Valuation & Return

Current vs industry vs history
Price-to-Tangible-Book 2.97
Earnings Yield (Joel Greenblatt) % -154.86

More Statistics

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 0
Positive ROA N
Positive CFROA N
Higher ROA yoy N
CFROA > ROA N
Lower Leverage yoy N
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy N